Skip to content

K-Stock Briefing

https://kstockbriefing.com

  • About Us
  • Weekly News
  • IR Room
  • RESEARCH
  • Disclosures
    • Semiconductors
    • Bio & Healthcare
    • Defense
    • Shipbuilding
    • Automotive
  • Toggle search form

[Disclosure] Hanwha Ocean (042660) – Provisional Financial Results (Fair Disclosure) / 2025-04-28

Posted on April 28, 2025August 8, 2026 By K-STOCK Editor No Comments on [Disclosure] Hanwha Ocean (042660) – Provisional Financial Results (Fair Disclosure) / 2025-04-28

Fact Source: Financial Supervisory Service DART

💡 3-Second Summary

This filing discloses Hanwha Ocean’s provisional Q1 2025 consolidated results, reporting consolidated revenue of KRW 3.14T (up 37.6% YoY) and operating profit of KRW 258.6B (up 388.8% YoY).

📊 Key Filing Details & Key Figures Summary

1. Q1 2025 Consolidated Provisional Results (Unit: 100M KRW, %)

  • Revenue:
    • Q1 2025: 31,431 (-3.4% QoQ, +37.6% YoY)
    • Q1 2025 Cumulative: 31,431 (+37.6% YoY)
  • Operating Profit:
    • Q1 2025: 2,586 (+53.0% QoQ, +388.8% YoY)
    • Q1 2025 Cumulative: 2,586 (+388.8% YoY)
  • Profit Before Income Tax Expenses:
    • Q1 2025: 2,172 (-3.6% QoQ, +303.0% YoY)
    • Q1 2025 Cumulative: 2,172 (+303.0% YoY)
  • Net Profit:
    • Q1 2025: 2,157 (-62.8% QoQ, +322.9% YoY)
    • Q1 2025 Cumulative: 2,157 (+322.9% YoY)
  • Net Profit Attributable to Owners of Parent:
    • Q1 2025: 2,157 (-62.8% QoQ, +322.9% YoY)
    • Q1 2025 Cumulative: 2,157 (+322.9% YoY)

2. Other Key Reference Information

  • Prepared in accordance with K-IFRS consolidated standards and rounded at the 100-million KRW level
  • Figures are provisional and subject to change during the external audit process
  • Related filing: Pre-announcement of Financial Results dated April 14, 2025

📝 Editor’s Comment (Key Follow-up Checkpoint)

📌 Verification of Final Audit Results via Periodic Quarterly Report

This disclosure reports provisional Q1 2025 performance prior to the completion of external auditor review, showing significant year-over-year gains in operating profit and net profit. Verifying the final audited figures and detailed notes in the upcoming official Quarterly Report is important for assessing the sustainability of operational growth. Relevant details can be reviewed in the forthcoming Quarterly Report and company IR Presentation materials.

📢 Disclaimer & Source Information

Source: This content was structured and newly written based on officially submitted data from the Financial Supervisory Service’s Data Analysis, Retrieval and Transfer System (DART).

Investment Disclaimer: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial liabilities rest entirely with the investor.

Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.

Search by
Company Name or Stock Ticker.
Disclosures, Shipbuilding

Post navigation

Previous Post: [Disclosure] Hanwha Ocean (042660) – New Facility Investment / 2025-04-28
Next Post: [Disclosure] Hanwha Ocean (042660) – Sales and Supply Contract / 2025-04-28

Related Posts

[Disclosure] HPSP (403870) – Change of CEO / 2025-11-07 Semiconductors
[Disclosure] Samsung Electronics (005930) – Decision on Cash and In-Kind Dividend / 2024-10-31 Semiconductors
[Disclosure] Wonik IPS (240810) – Change in Revenue or Income Structure Exceeding 30% (15% for Large Corporations) / 2026-02-25 Semiconductors
[Disclosure] Daeduck Electronics (353200) – Investor Relations (IR) Holding (Information Disclosure) / 2024-04-18 Semiconductors
[Disclosure] Hanwha Systems (272210) – Signs KRW 163.9B Supply Contract with KAI for LAH 2nd Mass Production Disclosures
[Disclosure] HPSP (403870) – Additional Listing (Exercise of Stock Options) / 2024-11-20 Semiconductors

Leave a Reply Cancel reply

You must be logged in to post a comment.

  • [Disclosure] Hanwha Ocean (042660) – Clarification on Rumors or Reports (Unconfirmed) / 2026-08-07August 7, 2026
  • [Disclosure] ALTEOGEN (196170) – Exclusive License Agreement for Recombinant Human Hyaluronidase Product ALT-B4 / 2026-08-05August 5, 2026
  • [Disclosure] ALTEOGEN (196170) – Ex-Rights (Bonus Issue) / 2026-08-04August 4, 2026
  • [Disclosure] ALTEOGEN (196170) – Market Measures on Stock Futures and Options (Bonus Issue) / 2026-08-04August 4, 2026
  • [Disclosure] Celltrion (068270) – CT-P44 (Darzalex Biosimilar) Korea Phase 3 Clinical Trial Plan Amendment Application / 2026-08-03August 3, 2026

Copyright © 2026 K-Stock Briefing.

Powered by PressBook Grid Dark theme